HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease-Reference-Cited by-同舟云学术

HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease

Published:2017-12-22 Issue:5 Volume:47 Page:615-620
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Wilson A.¹²³,Jansen L. E.⁴,Rose R. V.⁵,Gregor J. C.²,Ponich T.²,Chande N.²,Khanna R.²,Yan B.²,Jairath V.²⁵,Khanna N.²,Sey M.²,Beaton M.²,McIntosh K.²,Teft W. A.¹,Kim R. B.¹^ORCID

Affiliation:

1. Division of Clinical Pharmacology; Department of Medicine; Western University; London ON Canada

2. Division of Gastroenterology; Department of Medicine; Western University; London ON Canada

3. Department of Physiology and Pharmacology; Western University; London ON Canada

4. London Health Sciences Centre; London ON Canada

5. Department of Epidemiology and Biostatistics; Western University; London ON Canada

Funder

Canadian Institutes of Health Research

Cancer Care Ontario

Canadian Association of Gastroenterology

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.14483/fullpdf

Reference20 articles.

1. Azathioprine maintains long-term steroid-free remission through 3 years in patients with steroid-dependent ulcerative colitis;Chebli;Inflamm Bowel Dis,2010

2. American Gastroenterological Association institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease;Terdiman;Gastroenterology,2013

3. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the toronto consensus;Bressler;Gastroenterology,2015

4. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial;Panccione;Gastroenterology,2011

5. Infliximab, azathioprine, or combination therapy for Crohn's disease;Colombel;N Engl J Med,2010

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD);Česko-slovenská pediatrie;2024-08-01

2. Inflammatory Bowel Disease: A Comprehensive Analysis of Molecular Bases, Predictive Biomarkers, Diagnostic Methods, and Therapeutic Options;International Journal of Molecular Sciences;2024-06-27

3. Genomic Profiling for Predictive Treatment Strategies in Fibrotic Interstitial Lung Disease;Biomedicines;2024-06-21

4. Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study;Journal of Gastroenterology;2024-04-08

5. HLA-DQA1*05 correlates with increased risk of anti-drug antibody development and reduced response to infliximab in Chinese patients with Crohn’s disease;Gastroenterology Report;2023-12-22